{"groups":[{"description":"c-MET high (\\> 50%), RON null (0-9%)\n\nCrizotinib: All arms will receive crizotinib.","id":"FG000","title":"Cohort 1"},{"description":"c-MET + (10-100%), RON + (10-100%)\n\nCrizotinib was administered orally at 250 mg twice daily.","id":"FG001","title":"Cohort 2"},{"description":"c-MET null (0-9%), RON + (10-100%)\n\nCrizotinib was administered orally at 250 mg twice daily.","id":"FG002","title":"Cohort 3"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Early Study Termination"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}